

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Raludotatug deruxtecan (R-DXd) is an antibody-drug conjugate directed against...
 - a. FRα
 - b. CDH6
 - c. HER2
 - d. XPO1
2. Selinexor demonstrated the largest benefit in which of the following disease states?
 - a. TP53-wild-type ovarian cancer
 - b. TP53-mutant ovarian cancer
 - c. TP53-wild-type endometrial cancer
 - d. TP53-mutant endometrial cancer
 - e. TP53-wild-type cervical cancer
 - f. TP53-mutant cervical cancer
3. The DESTINY-PanTumor02 trial reported tumor responses with trastuzumab deruxtecan (T-DXd) in which gynecological tumor(s)?
 - a. Ovarian cancer
 - b. Endometrial cancer
 - c. Cervical cancer
 - d. All of the above
 - e. None of the above
4. Which of the following is true regarding tumor responses in gynecologic cancers with T-DXd in the DESTINY-PanTumor02 trial?
 - a. Tumor responses were seen only in the IHC 3+ cohort
 - b. Tumor responses were seen in both the IHC 3+ and IHC 2+ cohorts
 - c. Tumor response rates were around 30-40% in the all-comers population
5. What is the duration of niraparib therapy given to patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy in the PRIMA/ENGOT-OV26 study?
 - a. 1 year
 - b. 2 years
 - c. 3 years